Clinical Implications of Co-administering Apixaban with Key Interacting Medications.
Clin Pharmacol Drug Dev
; 13(9): 961-973, 2024 Sep.
Article
in En
| MEDLINE
| ID: mdl-39046333
ABSTRACT
With many available data sources, clinicians need to consider the benefit-risk profile of individual anticoagulants when balancing the need for anticoagulation, including evaluating the risks in patients with comorbidities and potential drug-drug interactions. This narrative review presents clinical data across multiple phases of drug development for the use of apixaban, a selective factor Xa inhibitor, when taken concomitantly with other agents, and evaluates the benefit-risk profile of apixaban with these interacting medications. Key subgroup analyses from the phase 3 ARISTOTLE trial (NCT00412984) are presented using data from patients who received either concomitant inhibitors or inducers of cytochrome P450 3A4 and/or Pglycoprotein. We also review the available evidence for the use of apixaban in patients with cancer-associated thromboembolism, as well as the use of apixaban in patients with COVID-19.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pyrazoles
/
Pyridones
/
Drug Interactions
/
Factor Xa Inhibitors
Limits:
Humans
Language:
En
Journal:
Clin Pharmacol Drug Dev
/
Clinical pharmacology in drug development
/
Clinical pharmacology in drug development (Online)
Year:
2024
Document type:
Article
Affiliation country:
Estados Unidos
Country of publication:
Estados Unidos